There is not a lot of information about primary medication nonadherence, but it could have a huge impact on patients, as discussed by a speaker at the Academy of Managed Care Pharmacy Nexus 2015 meeting.
There is not a lot of information about primary medication nonadherence (PMN), but it could have a huge impact on patients, as discussed by a speaker at the Academy of Managed Care Pharmacy Nexus 2015 meeting, held in Orlando, Florida, October 26-29.
PMN is when a new prescription is written for a medication or for a medication a patient has received before and a certain amount of time passes and the patient fails to pick up the medication during that time period, explained Rebekah Hanson, PharmD, BCPS, BCACP, clinical pharmacist at the University of Illinois at Chicago.
“When you think about the potential impact this could have on patients, if the patient doesn’t start on medication … well, the outcome is going to be very poor in those circumstances,” Dr Hanson said.
Literature has put PMN at anywhere from 5% to 30% of patients, but it is really underrepresented in the literature and there is more information on secondary medication nonadherence (SMN). SMN is likely easier to measure since it’s a matter of persistency, taking the medication on time, etc, she said.
The most common way of identifying PMN is by running e-prescribing data and claims data. There are some efforts to look at orders entered into electronic medical records at the point of entry and then the pick up data at the pharmacy, but there are limitations including: some prescriptions are still written; there are technical glitches; some patients receive samples, which means there is no way to know they started on therapy; some patients pay in cash; and it may be a duplicate prescriptions.
According to Dr Hanson, there are also a number of reasons for PMN:
There are also issues that are specific to specialty pharmacy, which hasn’t really been studied, but there have been studies about why patients might delay treatment:
There are interventions that can be used and the earlier they are initiated the better the outcome, Dr Hanson said. Although these interventions haven’t been studied in specialty pharmacy, she said that many specialty pharmacy services already implement interventions like postcard reminders, telephone reminders, and automated outreach as standard care.
Second CRL for Rivoceranib/Camrelizumab for Unresectable HCC
March 21st 2025Despite resubmitting after an initial complete response letter (CRL) due to manufacturing issues, the combination therapy received a second CRL as a frontline therapy for unresectable hepatocellular carcinoma (HCC).
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen